Placental Insufficiency Clinical Trials

Find Placental Insufficiency Clinical Trials Near You

Oxford Luteal Dysfunction and Placental Insufficiency Study

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

High blood pressure (BP) affects approximately 1 in 10 pregnancies. About half of women with high blood pressure in pregnancy develop a serious complication called preeclampsia, which kills over 70,000 women and 500,000 babies every year worldwide. Despite its devastating impact, scientists know little about preeclampsia prevention or treatment. Research has shown that preeclampsia results mainly from an abnormal attachment of the placenta to the lining of the womb. In the first 8 weeks of pregnancy, placental attachment depends on the release of hormones (for example, progesterone) by a gland in the ovary called the corpus luteum. Low blood levels of progesterone in early pregnancy are associated with a reduced chance of having a live baby and higher risk of miscarriage. Giving progesterone to women at risk of miscarriage in early pregnancy reduces their chance of developing preeclampsia by nearly 40%. These results highlight the crucial role of the corpus luteum in normal pregnancy, but there is a need for high-quality studies to identify women whose corpus luteum may be defective. Giving these women medicines to treat corpus luteal defects may lead to normal attachment of the placenta, reducing the risk of pregnancy complications such as preeclampsia. The investigators propose a study that will investigate whether ultrasound features of the corpus luteum and blood and urine levels of corpus luteal hormones may predict preeclampsia.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 16
Healthy Volunteers: t
View:

• Participant is willing and able to give written informed consent for participation in the study.

• Female, aged 16 years or above. As in vitro fertilisation is not undertaken in women younger than 18 years, those with pregnancies resulting from natural cycle frozen embryo transfer will be aged 18 years or above.

• Pregnancy \<8 completed weeks of gestation (i.e., up to 7 weeks and 6 days' gestation).

• Conception through any of the following means: unassisted (natural), ovulation induction (with clomifene citrate, letrozole or gonadotropin injections, including trigger injection), intrauterine insemination (with or without ovulation induction, including trigger injection), or natural cycle frozen embryo transfer.

• Intrauterine viable pregnancy confirmed on research ultrasound scan.

• Intention to deliver at Oxford University Hospitals.

Locations
Other Locations
United Kingdom
Oxford University Hospitals NHS Foundation Trust
RECRUITING
Oxford
Contact Information
Primary
Pedro Melo, MD PhD MRCOG
pedro.melo@wrh.ox.ac.uk
01865 221021
Time Frame
Start Date: 2026-10-23
Estimated Completion Date: 2028-12
Participants
Target number of participants: 360
Treatments
Healthy pregnant volunteers
Healthy pregnant volunteers at \<8 completed weeks of gestation (i.e., up to 7 weeks and 6 days' gestation)
Sponsors
Leads: University of Oxford

This content was sourced from clinicaltrials.gov